Introduction
Impaired immunity is an undeniable part of Alzheimer’s disease (AD) pathophysiology, although its direct contribution to disease onset and progression is still much debated [
1]. The main cellular components of the adaptive immunity are B and T lymphocytes, ultimately responsible for humoral (antigen-specific antibody secretion) and cell-mediated immunity. The adaptive immune response plays a key role in the development of adequate control against pathogens, cancer cells, and toxic molecules including misfolded tau and amyloid-beta peptide (Aβ) proteins [
2,
3].
The triple transgenic (3xTg-AD) mouse model displays tau and Aβ (amyloid plaques) accumulation in the brain increasing with age, as well as changes in their immune system [
4‐
8]. In the blood of 3xTg-AD mice, we previously reported that while granulocytes are not significantly affected, total leukocytes, B, and both CD4
+ and CD8
+ T lymphocytes are decreased compared with controls [
4]. Interestingly, we further observed an increase in CD4/CD8 T lymphocyte ratio suggesting an imbalance between helper/cytotoxic cells [
4]. These results suggest an overall deficit in adaptive immune response and are consistent with data reporting aberrant lymphocyte populations in AD individuals [
9‐
14].
To better decipher the causes and consequences of these modulations on immune response, we investigated hematopoietic cells in primary (bone marrow) and secondary (spleen) lymphoid organs along with in vivo lymphocyte activation cues from blood cytokine and immunoglobulin G (IgG) production in the 3xTg-AD model. We observed decreased levels of short-term reconstituting (STR) hematopoietic stem cells in the bone marrow. Furthermore, results from immunoglobulin G (IgG) and cytokine quantification suggest increased B and T lymphocyte activation respectively. Finally, elevated levels of interleukin (IL)-2, IL-17 and granulocyte-macrophage colony-stimulating factor (GM-CSF) strongly point to Th17 polarization in the 3xTg-AD model of tau and Aβ neuropathologies.
Discussion
In this study, we sought to deepen our understanding of the relationship between adaptive immune-related impairments and AD neuropathology, using the 3xTg-AD mouse model. Lymphocyte proportions were not changed in the primary and secondary lymphoid organs investigated, but the concentrations of hematopoietic STR in the bone marrow were decreased. We also reported evidence of increased B and T lymphocyte activation along with Th17 polarization in the 3xTg-AD mice, before the overt accumulation of Aβ and tau pathologies. These changes also occurred in the absence of Aβ and tau genetic expression in immune cells, consistent with a crosstalk between the CNS and peripheral immune cells. Interestingly, some of these modifications have also been described in AD patients (Table
2), validating this animal model for the study in immune changes in AD.
Table 2
Comparison of adaptive immunity defects observed in the 3xTg-AD model and human AD
Hematopoietic stem cells | Decreased bone marrow multipotent progenitorsa | Reduced circulating CD34 + hematopoietic stem cells [ 18] |
B lymphocytes | Increased plasma cells in bone marrowa Decreased in circulation [ 4] | Decreased in circulation [ 11, 72, 73] |
B lymphocyte antibody secretion | Increased IgGa | |
T lymphocytes | Decreased circulating helper (CD4) and cytotoxic (CD8) lymphocytes [ 4] Increased Th17 polarizationa | Increased circulating Th17 lymphocytes in early AD [ 47] |
CD4+/CD8+ ratio | | Increased [ 14, 76]; no change [ 72, 73, 75]; decreased [ 9] |
Plasma IL-1α concentration | | Decreased [ 77, 78]; no change [ 75] |
Other plasma cytokines | Increased IL-2, IL-17 and GM-CSFa Increased IL-12, decreased IL-1β, IL-5, IL-6, IL-17, TNF-α, IFN-γ, CCL2, CCL3, CCL5, CCL11, and GM-CSF [ 59] | Increased GM-CSF [ 76, 79] Increased or no change in IL-1, IL-6, IL-10; Increased IL-4, Il-12, IL-16, Il-18; decreased, increased, or no change in TNF-α (for review see [ 80]) |
Cell surface markers of hematopoietic progenitors are different between humans and mice. In humans, cells expressing the cell surface antigen CD34 are capable of reconstituting long-term, multi-lineage hematopoiesis [
29,
30]. Numbers of CD34
+CD45RO
low hematopoietic stem cells were found to be lower in the blood of 23 individuals with early AD compared to 25 Controls [
18]. Interestingly, reduced common lymphocyte progenitors are also observed in aged normal mice [
31,
32]. Therefore, decreased levels of STR reported here could reflect premature aging of the immune system in the 3xTg-AD model, and suggest that Aβ/tau pathological changes progressively developing in the brain can have an impact on immunological readouts in the periphery.
Antigen presentation, maturation of immunocompetent lymphocytes, and expansion of specific T and B lymphocytes take place in secondary organs, with the lymph nodes funneling lymph and the spleen filtering blood-derived antigens [
33]. In AD, Aβ peptides and tau protein have been detected in blood and/or lymph where they can migrate to secondary lymphoid organs and trigger lymphocyte activation [
34‐
39]. Recent research suggests that the meningeal lymphatic system and the cervical lymph nodes play a key role in the clearance of cerebral Aβ peptide [
36,
40]. Increased naïve and decreased effector T cells (both CD4
+ and CD8
+) were reported in the deep cervical lymph nodes of 5xFAD mice along with increased CD8
+ effector cells in their brains [
41]. Animal models of cerebral amyloidosis present T cell infiltration in the brain, which does not associate with beta-amyloid plaques [
42]. In contrast however, T cells have not been detected in the brains of 3xTg-AD mice [
43]. In a previous study, we reported a decrease of T lymphocytes in the blood of 3xTg-AD mice [
4], associated with higher GM-CSF, IL-12, and IL-5 brain concentrations. Although IL-5 and GM-CSF can be secreted by T lymphocytes, levels of more T-specific cytokines such as IL-2 or IL-17 remained similar to NTg [
4]. Therefore, more extensive studies are needed to clarify the role of cerebral T cells in AD pathology.
The increased activation of lymphocytes observed in 3xTg-AD mice could reflect engagement of the adaptive immune response to the removal of AD-related toxic proteins [
2]. In agreement with this, we observed higher IgG concentrations in the cortex of 3xTg-AD mice, although no accumulation was seen in amyloid plaques. However, chronic antigenic stress can lead to immune exhaustion [
10]. Therefore, immunotherapies against Aβ and tau proteins could gain from the use of both active and passive immunization strategies in order to maintain the immune balance [
44‐
46]. In line with our results, increased activation of circulating lymphocytes [
10,
11] together with lower number of naive T lymphocytes [
9,
10,
12] were reported in AD patients. Interestingly, cytokine quantification suggests Th17 polarization following helper T lymphocyte activation. Increased circulating Th17 lymphocytes have been reported in early AD [
48]. These cells are associated with immunopathogenesis of autoimmune disorders and could promote neuroinflammation in AD [
12,
41].
The 3xTg-AD mouse was generated from presenilin 1 (PS1
M146V) knockin embryos co-microinjected with APP
swe and tau
P301L Thy1.2 constructs [
7,
15]. While transgene expression of tau and Aβ is limited to the brain and spinal cord [
15], Aβ in the blood or peripheral organs has also been detected in this model [
6,
34,
36,
49]. Increased circulating tau is also detected in AD patients [
50‐
52]. It can thus be speculated that transport of Aβ and tau to the periphery induced an abnormal adaptive immunity response. Moreover, immune cells can cross the blood-brain barrier in AD and induce a cerebral immune response, which may lead to or sustain peripheral immune changes [
53]. In any cases, these observations in the 3xTg-AD model lend support to the hypothesis that AD neuropathology may play a causal role in anomalies of peripheral adaptive immunity.
On the other hand, it should be noted that the human presenilin 1 protein expressed in the 3xTg-AD model is under the control of its murine endogenous promoter. Interestingly, in the immune system, presenilins have been implicated in proliferation and signal transduction events in B lymphocytes as well as in thymocytes apoptosis, T lymphocyte expansion, and cytokine production [
54‐
56]. A recent study further demonstrated that, following oxidative stress, the lymphocytes isolated from individuals with familial AD-associated presenilin 1 mutations showed lower depolarization of mitochondrial membrane along with decreased apoptosis rate compared to lymphocytes from sporadic AD [
57]. In addition to potential tau/Aβ-related immune activation, the expression of mutant presenilin 1 in immune cells could therefore trigger some of the lymphocyte impairments observed here.
Previous results from spleen lymphocyte quantification in this model have yielded controversial data. For example, reduced [
8], unchanged [
58], and increased [
59] levels of T lymphocytes have been reported in the spleen of 2- and 12-month-old males, 4-month-old males, and 14- and 24-month old 3xTg-AD mice (males and females), respectively. In the study by Yang and colleagues, which reported increased levels of T lymphocytes, the investigators used C57Bl/6 controls instead of B6129 mice [
59]. The age, sex, and exact controls used in each study could therefore explain some differences observed.
In contrast with our previous results based on blood analyses [
4], we did not observe lower levels of lymphocytes in the primary and secondary lymphoid organs investigated in 12-month-old 3xTg-AD mice. In healthy humans, lymphocytes present in the blood only account for approximately 2% of the total lymphocyte pool; the other 98% being distributed throughout the body [
60]. Their mean transit time in the blood is evaluated to about 30 min compared to several hours in secondary lymphoid organs such as the spleen [
60,
61]. Therefore, small, statistically undetected alterations in lymphocyte composition in the spleen and bone marrow could cause major alterations in the blood [
60].
Discrepancy between lymphocyte concentrations in blood and lymphoid organs between 3xTg-AD and NTg mice could also be explained by deficient egress in the 3xTg-AD animals. Sphingosine-1-phosphate (S1P), a lipid mediator, has been identified as the driving force that mediates egress of lymphocytes from lymphoid organs depending on S1P concentration gradient, which is low in lymphoid organs and high in blood and lymph [
33,
61,
62]. In AD, levels of S1P are reduced in human brain samples [
63,
64], whereas it has been shown to protect cultured cortical neurons against Aβ toxicity [
65]. S1P receptors S1P
1, S1P
2, and S1P
3 are expressed in cerebral endothelial cells [
66] and regulate barrier integrity, which is critical to the control of central nervous system inflammation (reviewed in [
67]). Therefore, impaired S1P signaling could exacerbate the neuropathological progression in AD models. FTY720 is an agonist of S1P receptor (S1PR). Although it causes the depletion of circulating lymphocytes, treating 5xFAD mice with FTY720 decreases levels of Aβ peptides in the frontal cortex along with reduction of activated microglia [
68]. However, the lower dose (1 mg/kg/day) was more effective than the higher dose (5 mg/kg/day), suggesting that suboptimal S1PR agonist could be preferred in AD therapy [
68]. In AD, egress impairments could also result from increased cortisol. Indeed, whereas plasma cortisol concentrations are higher in AD [
69,
70], a robust rise of plasma cortisol in a mouse model of acute traumatic brain injury was linked to transient lymphocytopenia that was reversed by injection of S1P or rolipram, highlighting a complex and tightly regulated mechanism of lymphocyte egress [
71].